Navigation Links
WellPoint's Contribution To Drug Formulary Evaluation Standards Highlighted in ISPOR Publication
Date:7/2/2009

WellPoint is one of few in the industry providing public access to formulary evaluation standards

INDIANAPOLIS, July 2 /PRNewswire-FirstCall/ -- WellPoint Inc.'s (NYSE: WLP) contribution to creating evidence-based formulary evaluation standards is discussed in the June edition of Value in Health, the journal of the International Society for Pharmacoeconomics and Outcomes Research.

WellPoint is one of few health care management companies that publicly shares its standards on how it establishes its formulary, according to the article, entitled, "Health Technology Assessment in Health-Care Decisions in the United States." The standards are accessible by going to https://www.wellpointnextrx.com/wps/portal/wpo/consultant/druglist/consultantpharmacytherapeutics.

The article was authored by the University of Washington's Sean Sullivan and Scott Ramsey, Premera Blue Cross' John Watkins and WellPoint Chief Clinical Pharmacy Officer Brian Sweet. The publication was funded by a small honorarium from the International Society for Pharmacoeconomics and Outcomes Research.

The authors predict that these evidence-based standards--known as health technology assessment guidelines--will be pushed into a new realm as new evidence is generated from comparative effectiveness research.

"Much of the existing research we have on products is based on how the product performs against a placebo," said Sweet. "That simply isn't enough to ensure that every person gets the treatment that is best for him or her. To improve the quality of health care and to reduce medical costs, we need to know which approach works best and for whom. Comparative effectiveness research can provide additional evidence to be used in formulary evaluations to ensure we make the best health care decisions for our members."

WellPoint revised its evidence requirements for pharmaceutical technology assessments in October, 2008, and shared information about the type of data the company is using to make healthcare decisions on drug therapy with the pharmaceutical and biotechnology industries.

The WellPoint Outcomes-Based Formulary process includes specific requirements for new products, new indications and new formulations and the re-evaluation of products, indications and formulations. Specifically, it asks pharmaceutical manufacturers to provide the following:

  • Impact on patient-reported outcomes, including patient satisfaction, as well as quality of life
  • Potential for medical cost offsets in direct total costs of care and the impact per member per year costs.
  • Potential productivity impacts of introducing patients to the new product
  • Product performance and cost-effectiveness data for up to three years

"Our purpose in sharing this information is to provide drug companies with a clear sense of what we are looking for and to encourage them to invest in research that will produce more meaningful information, which can be used by WellPoint, physicians and members to work toward better health and lower costs," Sweet said.

About WellPoint, Inc.

WellPoint is committed to improving the lives and health of the people and communities we serve by simplifying the connection between health, care and value. Our goal is to help shape the impact each health care decision has on individuals, the health care system at-large, and our communities. WellPoint's more than 42,000 associates work every day to help create the best health care value for our customers. Through collaborations with providers and with innovative programs, WellPoint's affiliated health plans reward healthy lifestyles and quality, safe and effective care. As the nation's largest health benefits company, with more than 35 million members in its affiliated health plans, WellPoint is at the center of the health care system. This position provides us with the relationships and insights needed to help create affordable and actionable solutions that improve health care.

As an independent licensee of the Blue Cross and Blue Shield Association, WellPoint serves members as the Blue Cross licensee for California; the Blue Cross and Blue Shield licensee for Colorado, Connecticut, Georgia, Indiana, Kentucky, Maine, Missouri (excluding 30 counties in the Kansas City area), Nevada, New Hampshire, New York (as the Blue Cross Blue Shield licensee in 10 New York City metropolitan and surrounding counties and as the Blue Cross or Blue Cross Blue Shield licensee in selected upstate counties only), Ohio, Virginia (excluding the Northern Virginia suburbs of Washington, D.C.), Wisconsin; and through UniCare. Additional information about WellPoint is available at www.wellpoint.com.


'/>"/>
SOURCE WellPoint, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Health Insurance Industry Contributions to Politicians Block Regulation, Affordability in Health Care Debate, Says FTCR
2. THA Honors Nine Legislators for Contributions to Health Care
3. American Cancer Society Honors Outstanding Contributions to Fight Against Cancer
4. American Cancer Society to Present Highest Honor to Matthew L. Myers, Douglas R. Lowy, and Mark Schiffman for Outstanding Contributions to Cancer Fight
5. Will Rogers Institute to Honor Worlds Leading Geneticist and Recent Medal of Freedom Recipient, Dr. Francis S. Collins For His Outstanding Contribution to Lung Research.
6. Hooters of Gulfport Makes the Largest Contribution towards the $250,000 Donation to the V Foundation for Cancer Research
7. Childrens doctor honored by president of Colombia for contributions to pediatric cardiac care
8. Examination by National Expert Shows Blue Cross Blue Shield of Michigans Social Mission Contributions Totaled at Least $391 Million in 2007
9. MITs McGovern Institute honors Emory neuroscientist for contributions to psychiatry
10. UNIFEM and Avon Announce Partnership to End Violence Against Women and Advance Womens Empowerment: Company Contribution Benefits UN Trust Fund
11. Ford Launches Warriors in Pink Mustang for 09, Doubles Contributions To Race For The Cure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2017)... New York (PRWEB) , ... August 18, 2017 ... ... leading manufacturers and marketers of high-quality anti-aging skincare solutions, recently announced ... Serum. These new products are an affordable, yet effective alternative to expensive plastic ...
(Date:8/18/2017)... ... 18, 2017 , ... “Prompted By Love”: a love story thrown into doubt ... Nettles. Author Mary P. Nettles has devoted her life to ministry since the ... lifelong desire to write was, however, not fulfilled until 2014 when "The Color of ...
(Date:8/18/2017)... ... August 18, 2017 , ... “Case ... Veterans Affairs Medical Center. “Case #10-5411 Veterans Administration” is the creation of ... abuse. In June 1990, Carol Mulhem started work at the Coatesville VAMC ...
(Date:8/17/2017)... ... August 17, 2017 , ... ... organizations and considered extremely effective, very effective, or effective by 85% of respondents, ... , NEJM Catalyst Insights Reports are based on surveys of the NEJM Catalyst ...
(Date:8/17/2017)... ... , ... When Amy Cowperthwait left the emergency room after 28 ... dream to make nursing education more relevant and prepare aspiring nurses to address both ... healthcare provider education. , “The human element was missing. Students were learning ...
Breaking Medicine News(10 mins):
(Date:8/2/2017)... , Aug. 2, 2017 CaryRx, a next-generation full-service ... delivery service for patients in the Washington D.C. ... retail pharmacy by providing delivery of medications through the convenience ... future delivery or delivered within one hour to any location ... excited to bring this invaluable service to Washington ...
(Date:7/31/2017)... , July 31, 2017 7D Surgical, developer ... Medical has purchased the 7D Surgical System to support its ... Washington D.C. and Virginia.  7D Surgical has ... for many of the premier medical facilities within those markets. ... ...
(Date:7/27/2017)... Services, Inc. (NYSE: WST ) today announced ... financial guidance for the full-year 2017. ... Reported net sales of $397.6 million, a record high, ... constant currency (organic) grew by 3.9%. ... in the prior-year quarter. Second-quarter 2017 adjusted diluted EPS ...
Breaking Medicine Technology: